ADREXpharma, a leading pharmaceutical company known for its expertise in the development, distribution and marketing of medical cannabis, and Mother Labs, a leading IP and genetics company from Canada, are pleased to announce their strategic partnership . Together, a premium line of cannabis flowers is launched on the German market under the name “Mother Labs”, which offers medical patients incomparable quality and innovation.
This exclusive collaboration combines ADREXpharma’s extensive experience in the areas of pharmaceutical sales, regulatory affairs and market dynamics with the state-of-the-art development and crossing experience of genetics through Mother Labs. “This partnership represents an important milestone in our mission to provide German patients with the highest quality medical cannabis products“said Nicole Broockmann, CEO of ADREXpharma. “Mother Labs’ advanced genetic development capabilities perfectly complement our sales and regulatory affairs expertise. Together we will launch a Mother Labs line that meets the highest quality and consistency requirements. “
Mother Labs is known for its innovative approach to cannabis breeding and is characterized by the development of individual types of cannabis that are tailored to the needs of patients. “We are happy to bring our advanced genetics to Germany in cooperation with ADREXpharma“said Brian Bain, CEO of Mother Labs. “Our specially built system with a special room for “pheno hunting” and extensive storage in our tissue culture laboratory enables us to test all genetics strictly internally for at least 72 weeks before approval. This precision process ensures that only the highest quality, most stable and unique genetics come onto the market,what our position as market leader in the field of genetic Strengthens innovation. “
Since the legalization of cannabis in 2019, Mother Labs has worked with many of the leading Canadian producers and has supplied the market with over 150 different genetics. The company has also built up a strong presence in international markets, including the UK, Australia and South Africa. Their continuous testing and expanding genetic resources drive innovation, which makes this partnership with ADREXpharma an important step in being able to offer first-class medical flowers.
The new flower line of the “Mother Labs” brand will initially be launched with a hand-picked selection of premium cannabis flowers, which are 3 varieties developed by Mother Labs in 2024.
The first 3 genetics will be available in all German pharmacies in October 2024.
ADREXpharma and Mother Labs are committed to meeting the highest standards for compliance, quality control and customer satisfaction when expanding their presence in the European market.
